Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Radiation-induced Dermatitis Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord

NCT03990597
View directory record Official record
Conditions
Central Nervous System Sarcoma, Ependymoma, Glioma, Malignant Intracranial Germ Cell Tumor, Medulloblastoma, Pineoblastoma, Primary Central Nervous System Neoplasm
Interventions
Placebo Administration, Questionnaire Administration, Wound Dressing Material
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 3, 2026, 9:57 PM EDT
Active, not recruiting Phase 1 Interventional

Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer

NCT05340673
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Agent Affecting Integumentary System, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 3, 2026, 9:57 PM EDT
Terminated Not applicable Interventional

Utilizing Topical Sodium Hypochlorite to Ameliorate Radiation Dermatitis

NCT04630821
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
Dilute Sodium Hypochlorite solution
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Sep 3, 2026, 9:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Topical Use of Difinsa53™ to Prevent Radiation Dermatitis

NCT02534129
View directory record Official record
Conditions
Radiodermatitis
Interventions
Difinsa53, Aquaphor
Drug
Lead sponsor
ProTechSure Scientific, Inc.
Industry
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

NCT02142959
View directory record Official record
Conditions
Breast Cancer
Interventions
Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion, 3D conformal radiation therapy
Drug · Radiation
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Phase 1Phase 2 Interventional

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

NCT04261387
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
LUT014 Gel, Placebo for LUT014 Gel
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Columbus, Georgia • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 3, 2026, 9:57 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

NCT01910818
View directory record Official record
Conditions
Chronic Radiation Dermatitis
Interventions
Fractional CO2 laser treatment, No treatment
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Bacterial Decolonization to Prevent Radiation Dermatitis

NCT03883828
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
Chlorhexidine gluconate solution, Mupirocin Ointment
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Not applicable Interventional Results available

Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy

NCT04173247
View directory record Official record
Conditions
Head and Neck Cancer, Radiation Dermatitis
Interventions
KeraStat Cream, Routine Skin Care - Commercially Available Agents
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 3, 2026, 9:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers

NCT00001150
View directory record Official record
Conditions
Dermatitis, Healthy, Neoplasm, Urticaria, Vesiculobullous Skin Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1976 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Results available

Silverlon to Reduce Radiation Dermatitis

NCT04238728
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
Silverlon
Device
Lead sponsor
University of Rochester
Other
Eligibility
22 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 3, 2026, 9:57 PM EDT
Completed No phase listed Observational

Determining Molecular Drivers of Radiation Dermatitis

NCT04764682
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 3, 2026, 9:57 PM EDT
Recruiting No phase listed Observational

Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy

NCT06953245
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Not applicable Interventional

LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis

NCT00573365
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
Gentlewaves Select™ handheld high energy LED array, Radiation
Device · Radiation
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer

NCT02556632
View directory record Official record
Conditions
Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
Interventions
Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Gary Morrow
Other
Eligibility
21 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Newark, Delaware • Decatur, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Not applicable Interventional Results available

KeraStat(R) Cream for Radiation Dermatitis

NCT03559218
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
KeraStat(R) Cream, Standard of care
Device · Other
Lead sponsor
KeraNetics, LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Sep 3, 2026, 9:57 PM EDT
Terminated Phase 2 Interventional

Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer

NCT04149522
View directory record Official record
Conditions
Breast Cancer, Radiotherapy; Adverse Effect, Dermatitis or Eczema, Radiotherapy Side Effect, Radiation Burn, Radiation Dermatitis, Radiotherapy; Complications
Interventions
Mepitel Film®
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Clairton, Pennsylvania • Monroeville, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 3, 2026, 9:57 PM EDT
Withdrawn Not applicable Interventional

KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer

NCT02168179
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Skin Reactions Secondary to Radiation Therapy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
dermatologic complications management/prevention, questionnaire administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 3, 2026, 9:57 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy

NCT01544504
View directory record Official record
Conditions
Radiodermatitis
Interventions
Norepinephrine
Drug
Lead sponsor
ProCertus BioPharm, Inc
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Not applicable Interventional

Acute Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer Patients With the Use of Silver-Plated Technology

NCT06831084
View directory record Official record
Conditions
Radiation Dermatitis Acute
Interventions
Silver plated technology (SPT) dressing
Device
Lead sponsor
Parul Barry
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients

NCT01042938
View directory record Official record
Conditions
Breast Cancer
Interventions
Curcumin C3 Complex, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2012 · Synced Sep 3, 2026, 9:57 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 3, 2026, 9:57 PM EDT
Terminated Phase 1 Interventional

Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients

NCT01263366
View directory record Official record
Conditions
Radiodermatitis
Interventions
Norepinephrine
Drug
Lead sponsor
ProCertus BioPharm, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Sep 3, 2026, 9:57 PM EDT